Literature DB >> 22454899

Metabolism of terbutaline in man and dog.

D S Davies1, C F George, E Blackwell, M E Conolly, C T Dollery.   

Abstract

1 The metabolism of terbutaline (1-(3,5-dihydroxyphenyl)-2-tertiarybutylamino-ethanol), a drug which acts selectively on β(2)-adrenoceptors has been studied in man and dog. 2 The sulphate conjugate of terbutaline was the only metabolite identified in plasma or urine from humans or dogs given the drug either orally or intravenously. We have confirmed that terbutaline, a resorcinol derivative, is not a substrate for catechol-0-methyl transferase in man or dog. 3 Metabolism of terbutaline was dependent upon the route of administration in man, but not in dog. In man, oral terbutaline was largely conjugated whereas drug administered intravenously appeared largely unchanged in urine. 4 Conjugation of oral terbutaline, which probably occurred during the `first-pass' through the gut wall or liver, was less than oral isoprenaline. This may explain why the poorly absorbed terbutaline is a more effective oral bronchodilator than isoprenaline, even though the latter drug is completely absorbed following oral dosing.

Entities:  

Year:  1974        PMID: 22454899      PMCID: PMC1402454          DOI: 10.1111/j.1365-2125.1974.tb00221.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  THE FATE OF 3H-ISO-PROTERENOL IN THE RAT.

Authors:  G HERTTING
Journal:  Biochem Pharmacol       Date:  1964-08       Impact factor: 5.858

2.  2 new groups of selective stimulants of adrenergic beta-receptors.

Authors:  J Bergman; H Persson; K Wetterlin
Journal:  Experientia       Date:  1969-09-15

3.  A clinical comparison of the effect of oral terbutaline and orciprenaline.

Authors:  H Formgren
Journal:  Scand J Respir Dis       Date:  1970

4.  The metabolism of terbutaline in vitro by rat and human liver O-methyltransferases and monoamine oxidases.

Authors:  K Persson; K Persson
Journal:  Xenobiotica       Date:  1972-07       Impact factor: 1.908

5.  The metabolism of terbutaline in man.

Authors:  H T Nilsson; K Persson; K Tegnér
Journal:  Xenobiotica       Date:  1972-07       Impact factor: 1.908

6.  Absorption and elimination profile of isoproterenol. 3. The metabolic fate of dl-isoproterenol-7-3H in the dog.

Authors:  W D Conway; H Minatoya; A M Lands; J M Shekosky
Journal:  J Pharm Sci       Date:  1968-07       Impact factor: 3.534

7.  Metabolism of isoprenaline in dog and man.

Authors:  M E Conolly; D S Davies; C T Dollery; C D Morgan; J W Paterson; M Sandler
Journal:  Br J Pharmacol       Date:  1972-11       Impact factor: 8.739

8.  Comparison of two oral selective beta2-adrenergic stimulant drugs in bronchial asthma.

Authors:  J S Legge; J Gaddie; K N Palmer
Journal:  Br Med J       Date:  1971-03-20

9.  Trial of new bronchodilator, terbutaline, in asthma.

Authors:  B J Freedman
Journal:  Br Med J       Date:  1971-03-20
  9 in total
  6 in total

1.  Drug metabolism by the gastrointestinal mucosa.

Authors:  C F George
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 2.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

3.  Salbutamol disposition and dynamics in conscious rabbits: influence of the route of administration and of the dose.

Authors:  S Perreault; H Ong; P du Souich
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

Review 4.  Pharmacokinetic optimisation of asthma treatment.

Authors:  A M Taburet; B Schmit
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

5.  New lipophilic terbutaline ester prodrugs with long effect duration.

Authors:  O A Olsson; L Å Svensson
Journal:  Pharm Res       Date:  1984-01       Impact factor: 4.200

Review 6.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.